These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16355344)

  • 21. Urolithiasis in HIV-positive patients treated with atazanavir.
    Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D
    Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
    Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
    J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-HIV agents. Kaletra + atazanavir.
    TreatmentUpdate; 2005; 17(5):5. PubMed ID: 17219657
    [No Abstract]   [Full Text] [Related]  

  • 26. Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.
    Ferraris L; Viganò O; Peri A; Tarkowski M; Milani G; Bonora S; Adorni F; Gervasoni C; Clementi E; Di Perri G; Galli M; Riva A
    J Antimicrob Chemother; 2012 Sep; 67(9):2236-42. PubMed ID: 22661571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
    Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia.
    Atrio JM; Sperling RS; Posada R; Rodriguez Caprio G; Chen KT
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):e158-9. PubMed ID: 23970241
    [No Abstract]   [Full Text] [Related]  

  • 29. Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.
    Morello J; Alvarez E; Cuenca L; Vispo E; González-Lahoz J; Soriano V; Rodríguez-Nóvoa S
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1043-5. PubMed ID: 21348813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia.
    Avihingsanon A; Tongkobpetch S; Kerr SJ; Punyawudho B; Suphapeetiporn K; Gorowara M; Ruxrungtham K; Shotelersuk V
    J Acquir Immune Defic Syndr; 2015 May; 69(1):e36-7. PubMed ID: 25622064
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
    Sahloff EG; Duggan JM
    Ann Pharmacother; 2006 Oct; 40(10):1731-6. PubMed ID: 16968825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.
    van Leeuwen E; Ter Heine R; van der Veen F; Repping S; Beijnen JH; Prins JM
    Antimicrob Agents Chemother; 2007 Jan; 51(1):335-7. PubMed ID: 17074793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV therapeutics, continued: another HIV protease inhibitor approved.
    Laurence J
    AIDS Read; 2003 Aug; 13(8):355-6. PubMed ID: 14524318
    [No Abstract]   [Full Text] [Related]  

  • 34. Atazanavir-related hyperbilirubinaemia is not highlighted in the British National Formulary.
    Bradbeer C; Ngwenya S; Baker P; George M
    Int J STD AIDS; 2012 Oct; 23(10):759. PubMed ID: 23104755
    [No Abstract]   [Full Text] [Related]  

  • 35. Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.
    East J; Blanton LS
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1081-3. PubMed ID: 22123706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDR1 C3435T polymorphism in patients with breast cancer.
    Turgut S; Yaren A; Kursunluoglu R; Turgut G
    Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load.
    Luz AJ; Poeta J; Linden R; Antunes MV; Caminha LI; Sprinz E
    Braz J Infect Dis; 2013; 17(6):657-60. PubMed ID: 23933406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.
    Turatti L; Sprinz E; Lazzaretti RK; Kuhmmer R; Agnes G; Silveira JM; Basso RP; Pinheiro CA; Silveira MF; de Almeida S; Ribeiro JP; Mattevi VS
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1015-8. PubMed ID: 22050734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient.
    Cattaneo D; Meraviglia P; Cozzi V; Baldelli S; Milani G; Clementi E
    Fundam Clin Pharmacol; 2012 Apr; 26(2):204-6. PubMed ID: 21210843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients.
    Winzer R; Langmann P; Zilly M; Tollmann F; Schubert J; Klinker H; Weissbrich B
    Ann Clin Microbiol Antimicrob; 2005 Jan; 4():3. PubMed ID: 15659247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.